References
- Andersen K, Launer LJ, Dewey ME et al ender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neumlogy 53 (9), 1992–1997 (1999).
- Copeland JR, McCracken CF, Dewey ME et al Undifferentiated dementia, Alzheimer's disease and vascular dementia: age- and gender-related incidence in Liverpool. The MRC-ALPHA Study. BE Bychiatry175, 433–438 (1999).
- Gambassi G, Lapane KL, Landi F, Sgadari A, Mor V, Bemabie R. Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease. Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) Study Group. Neurology53(3), 508–516 (1999).
- Ueki A, Shinjo H, Shimode H, Nakajima T, Morita Y. Factors associated withmortality in patients with early-onset Alzheimer's disease: a five-year longitudinal study. Int.j Geriatr Psychiatry16(8), 810–815 (2001).
- Cohen D, Eisdorfer C, Gorelick P et al. Sex differences in the psychiatric manifestations of Alzheimer's disease. j Geriatr Soc. 41(3), 229–232 (1993).
- McPherson S, Back C, Buckwalter JG, Cummings JL Gender-related cognitive deficits in Alzheimer's disease. Int. fiychogeriatr 11(2), 117–122 (1999).
- Heun R, Kockler M. Gender differences in the cognitive impairment in Alzheimer's disease. Atrh. Womens Mental Health 4, 129–137 (2002).
- Barrett AM.Probable Alzheimer's disease: gender-related issues. J. Gent/. Speed Med 2(1), 55–60 (1999).
- Ghebremedhin E, Schultz C, Thal DR et al Gender and age modify the association between APOE and AD-related neuropathology. Neurology 56 (12), 1696–1701 (2001).
- Siegel BV Jr, Shihabuddin L, Buchsbaum MS et al. Gender differences in cortical glucose metabolism in Alzheimer's disease and normal aging. J. NeuropTchiatry Gun. Neurosci 8(2), 211–214 (1996).
- Ott BR, Heindel WC, Tan Z, Noto RB. Lateralized cortical perfusion in women with Alzheimer's disease. J. Gentl Speed: Med. 3(6), 29–35 (2000).
- Craft S, Asthana S, Schellenberg G et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrino/ogy 70(2), 146–152 (1999).
- Cherry LM, Funk J, Lesser JM, Lesam M.Gender differences and the interpretation of genetic instability in Alzheimer's disease. Mutat. Res. 275(2), 57-67(1992).
- Bretsky PM, Buckwalter JG, Seeman TE et al. Evidence for an interaction between apolipoprotein E genotype, gender and Alzheimer's disease. Alzheimer Dis. Assoc. Disond 13(4), 216–221 (1999).
- Lambert JC, Harris JM, Mann D eta] Are the estrogen receptors involved in Alzheimer's disease? Neumsci. Lett. 306(3), 193–197 (2001).
- Adler C, Wilz G, Gunzelmann T 'I never feel free'-women care for the demented husband, father or mother. Gesundheitswesen. 58\(Suppl. 2), 125–131 (1996).
- Bedard M, Molloy DW, Pedlar D, Lever JA, Stones MJ. Associations between dysfunctional behaviors, gender and burden in spousal caregivers of cognitively impaired older adults. 1997 IPA/Bayer Research Awards in Psychogeriatrics. Int. Psychogeriatr. 9(3), 277–290 (1997).
- MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. int. J. Geriatr Psychiatry 13(9), 625–630 (1998).
- Rigaud AS, Traykov L, Caputo L et al The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer's disease. Eur I Neurology7, 255–258 (2000).
- Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50(3), 669–677 (1998).
- Compton J, van Amelsvoort T, Murphy D. HRT and its effect on normal ageing of the brain and dementia. BE J. Clin. Phatmacol 52(6), 647–653 (2001).
- Okiishi CG, Paradiso S, Robinson RG. Gender differences in depression associated with neurologic illness: clinical correlates and pharmacologic response. J. Gentl Speed: Med. 4(2), 65–72 (2001).
- Ott BR, Lapane KL, Gambassi G. Gender differences in the treatment of behavior problems in Alzheimer's disease. SAGE Study Group. Systemic Assessment of Geriatric drug use via Epidemiology. Neumlogy54(2), 427–432 (2000).